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Antibiotics are largely prescribed for cystic fibrosis (CF) respiratory exacerbations. Effects of antibiotics on the inflammatory profile of the
patients have been shown but remain controversial. Lipoxin A4 (LXA4) is a lipid mediator, reported to play a central role in resolving airway
inflammation. The aim of the study was to investigate the consequences of antibiotherapy on LXA4 and IL-8 levels in CF patients' airways.
Methods: Eighteen CF patients (7 females, median age 20, range 8 to 47 years) consecutively admitted at the CF center of Montpellier for
antibiotics during pulmonary exacerbation, were enrolled. Before and after antibiotics, all patients underwent spirometry (FEV1 and FVC),
bacterial cultures and cell counts in sputa. IL-8 and LXA4 concentrations were determined in sputum samples by the median of immunometric
assays.
Results: As previously reported, after antibiotics therapy, FEV1 and FVC significantly improved. While neutrophil cell counts and IL-8 levels
decreased, the LXA4 levels significantly increased after antibiotics therapy and were inversely correlated with IL-8 levels.
In conclusion, we reported a correlation between antibiotics treatments and inflammatory markers in CF sputum. Our data provide evidences
for a novel effect of antibiotics increasing the concentration of the anti-inflammatory lipid mediator LXA4.
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Chronic endobronchial infection and neutrophil-dominated
lower airway inflammation are hallmarks of cystic fibrosis (CF)
[1]. Currently, investigators are focused on developing new
medications to modify the bacterial and inflammatory environ-
ment of the CF airway to slowdown the progression of CF lung
disease. Lipoxins are biologically active eicosanoids produced
by lipoxygenases interactions. They are endogenous molecules
synthesised at inflammation sites and their anti-inflammatory
properties have been reported in several models [2,3]. The
effects of the endogenous lipoxin isomer, the LXA4 (5S,6R,15S-⁎ Corresponding author. Tel.: +33 467 336 089; fax: +33 467 330 740.
E-mail address: r-chiron@chu-montpellier.fr (R. Chiron).
1 Joint first authors.
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.04.002trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid) have been
reported on leukocyte trafficking via modulation of chemotaxis,
adhesion, transmigration and phagocytic clearance of apoptotic
neutrophils [4]. In airway epithelial cells, since the first de-
tection of LXA4 in bronchoalveolar lavage in 1990, it has been
reported that the production of LXA4 was fluctuating and found
to be decreased in the airways of CF patients with high neutro-
phil cell counts [5,6]. In CF, the safety and efficacy of new
therapies as well as the inflammatory mechanisms in airways,
have been studied using clinical outcomes such as spirometric
measurements (FEV1 and FVC), bacterial density, and measure-
ments of mediators of systemic and pulmonary inflammation
[1,7,8]. Classical therapies including physiotherapy, mucociliary
clearance, anti-inflammatory and antibiotics used for pulmonary
exacerbations in CF patients aim to reduce bacterial density
and inflammatory markers in expectorated sputum [9]. Mostd by Elsevier B.V. All rights reserved.
Table 1
General characteristics of CF patients before antibiotics treatment for pulmonary
exacerbation
n=18
Sex ratio (F/M) 7/11
Age in year (range) 22 (8–47)
Body Mass Index (P /T2) (percentiles) 50 (3–97)
Schwachman score (/100) 60 (35–94)
FVC (% predicted) 74 (51–104)
FEV1 (% predicted) 59 (32–101)
Thoracic CT-scan score (Bhalla score/25) 11.5 (8–15)
Pathogens in sputa samples
– P. aeruginosa
Intermittent colonization 6
Chronic colonization 11
– S. aureus 11
Multi Resistant S. aureus 4
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number of days spent in the hospital, and decreased requirement
for antibiotics as clinically relevant outcome measures. The
purpose of the present study was to identify the possible role for
antibiotherapy on the production of LXA4 and the pro-inflam-
matory cytokine, IL-8, in the airways of CF patients.
2. Methods
2.1. Study design
This was a prospective study in CF subjects who received
intravenous (IV) antibiotics in addition to routine therapies for
an acute pulmonary exacerbation. Objectives were to examine
changes in lung function, microbiology, white cell count, neu-
trophil count and IL-8 and LXA4 concentrations in sponta-
neous sputum after antibiotics therapy prescribed for pulmonary
exacerbation.
2.2. Subjects inclusion
Subjects were recruited from the CF center of Montpellier,
France. Adult subjects and parents of those less than 18 years of
age signed their informed consent approved by the Ethics
Committee of our Institution. Twenty six patients were re-
cruited. Recruitment criteria were the diagnosis of CF (chloride
sweat concentrations N60 mEq/L and/or two CFTR mutations),
an age greater than 6 years, an experience of pulmonary exa-
cerbation (defined as having at least three of the following:
increased cough or sputum, fever, weight loss, absenteeism
from school or work due to illness, tachypnea, new findings on
chest examination, decreased exercise tolerance, decreased
pulmonary function tests or oxyhemoglobin saturation, or a new
finding on chest radiograph) [9], treatment with at least one
intravenous antibiotic associated with another IV, oral or
nebulized antibiotic (recommended by the treating physician)
for a minimum of 14 days, and ability to perform spirometry
reproducibility. Exclusion criteria included pneumothorax,
hemoptysis, history of B. cepacia in sputum, inability to per-
form spirometry and inability to perform sputum collection.
Patients were investigated with pulmonary function tests and
sputum samples before (visit 1) and after (visit 2) antibiotic
treatment. Subjects were withdrawn if systemic steroids were
added or if changes in their chronic systemic steroid dose
occurred during the study. Among these 26 selected patients, 6
patients never expectorated spontaneously, 20 patients could
expectorate at first visit and 18 of them were able to expectorate
at both visits. Finally, 8 patients were excluded and 18 patients
were definitively included in the study. Subjects who completed
both sputum collections were included in the analyses of pul-
monary function, microbiology and inflammatory markers.
2.3. Sputum processing
For each included patient, sputum samples were collected
spontaneously after physiotherapy at both visits. The protocol
for sputum processing was adapted from that recommended bythe European Respiratory Society [10]. Two aliquots of whole
sputumweighing approximately 1 gwere taken from each sample
and processed within 2 h. One was used for bacterial density. The
other was treated, with freshly prepared 0.1% DTT (Calbiochem
Corp, San Diego, CA, USA) at a ratio of 4:1 (v/w) and rocked for
15 min at room temperature for inflammatory markers analysis.
After treatment each aliquot was filtrated. The sputum solution
phase was obtained by centrifugation (1200 rpm for 10 min at
4 °C) and the supernatant stored at −70 °C until required. The
remaining cells were counted after Trypan blue test of viability.
Specimens containing squamous epithelial cells of less than 50%
of the total inflammatory cell number were considered as suc-
cessful. At least 400 inflammatory cells were counted for each
sample and the percentage of eosinophils, neutrophils, macro-
phages and lymphocytes were recorded.
2.4. Detection of IL-8 and LXA4 in sputum
The IL-8 and LXA4 concentrations in the spontaneous
sputa of CF patients were measured by commercially available
enzyme-linked immunosorbent assay (ELISA) kit from Dia-
clone (Besancon, France) and Neogen Corporation (Lexington,
USA) respectively. The detection limits of the assay were 31.25
to 2000 pg/ml of IL-8 and 20 to 2000 pg/ml of LXA4. Each
sample was diluted as appropriated and processed in duplicate.
2.5. Statistical analyses
Results are given as medians and 25–75% percentiles. We
used the Wilcoxon (W) test for paired data to perform statistical
analysis. Correlation coefficient was calculated by the Spear-
man-Rank test (rho) and the significance was determined at the
0.05 level.
3. Results
3.1. Demographic and clinical characteristics of subjects
The clinical characteristics of the subjects are represented in
the Table 1. All patients but one had typical CF disease with
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creatic insufficiency. All patients had identified CFTR muta-
tions. Five patients were homozygous F508del and 11 were
heterozygous F508del. The othermutationswere:N1303K (n=3),
L997F (n=1); G542X (n=2); G85E (n=1); 1811+1.6KB AG
(n=1); W1282X (n=1); 3737delA (n=1) and 2789+5G (n=1).
Two patients had the genotype N1303K/3272-26ANG and 711+
1G-T/711+1G-T.
The duration of IV antibiotic therapy was 16.55 (14–21)
days, and there were 23.5 (14–30) days between study visits.
The time-lapse between the end of antibiotherapy and sputum
collection was 3.3 [1–9] days. All 18 subjects were treated with
a minimum of one IV antibiotic. The most frequently used IV
antibiotic was tobramycin (n=11) in association with IV cefta-
zidime (n=8), IV imipenem (n=1), oral ciprofloxacin (n=1) or
amoxcicillin and nebulized colistimethate (n=1). Other combi-Fig. 1. Inflammation markers in sputa of 18 cystic fibrosis patients before and
concentrations in ng/ml; (C) lipoxin A4 (LXA4) concentrations in ng/ml and LXA4/
bars indicate median values for each markers.nations were IV ceftazidime with oral ciprofloxacin (n=2), IV
piperacillin/tazobactam associated with rifampin (n=1) and IV
linezolide for Multi Resistant S. aureus infection in one case.
3.2. Changes in pulmonary function after antibiotic therapy
As previously reported, after antibiotic therapy, FEV1 and
FVC significantly improved by a median increase of 6% (−3 to
22%) and 10% (−1 to 18%) of predicted values respectively.
3.3. Changes in bacterial density after antibiotic therapy
All but one had P. aeruginosa isolated from sputum before
administration of IV antibiotics. Among these subjects, the
density of P. aeruginosa in induced sputum have a tendency to
decrease significantly from 8.1+2.3log10log10 CFU/g before toafter IV antibiotics. (A) Neutrophil cell counts in %; (B) interleukin-8 (IL-8)
neutrophil ratio and (D) IL-8 and LXA4 concentrations relationship. Horizontal
466 R. Chiron et al. / Journal of Cystic Fibrosis 7 (2008) 463–4683.8+2.1log10log10 CFU/g after antibiotics (pb0.001). The
patient without P. aeruginosaP. aeruginosa had Multi Resistant
S. aureus and Proteus isolated from sputum before IV anti-
biotics. The density of S. aureusS. aureus in sputum decreased
significantly from 7.8log10log10 CFU/g before to 4.2 log10log10
CFU/g after IV antibiotics. In 2 cases, several other pathogens
were found in association with intermittent P. aeruginosaP.
aeruginosa bronchial colonization: S. pneumoniae (6 log10
CFU/glog10CFU/g) (n=1) and A. xilososidans (4 log10log10
CFU/g) (n=1) and H. influenzae (4 log10 CFU/glog10CFU/g)
(n=1). Only A. xilososidansA. xilososidans was found after
antibiotic therapy at the same concentration.
3.4. Changes in inflammatory markers and lxa4 levels after
antibiotic therapy
Mean indicators of each inflammatory marker including total
white cell count, neutrophil count, percent neutrophils, and IL-8
levels in sputum decreased significantly after IVantibiotic therapy.
While median neutrophil counts and IL-8 levels decreased
from 90 to 68% (Fig. 1A) and from 12.7 to 8.5 ng/ml (Fig. 1B)
respectively, median LXA4 levels significantly increased after
antibiotic therapies from 15.9 to 45.5 ng/ml. The median LXA4/
neutrophil ratio showed an amplified increase from 0.19 to 0.63
(Fig. 1C). Despite the significant changes of the median values,
for 6 patients, no significant change in IL-8 and LXA4 could be
found, whereas for the rest of the 12 patients, IL-8 decreased by
50%, and LXA4 levels were tripled. Finally, an inverted cor-
relation between the overall IL-8 and LXA4 levels in sputum
was found (Fig. 1D).
4. Discussion
In the present study, we have shown that 2 weeks of IV
antibiotic treatment for pulmonary exacerbation in CF which
resulted in improved pulmonary function was associated with
changes in several markers detected in spontaneously expecto-
rated sputum. Specifically, we observed a reduction of bacterial
density, neutrophil count and IL-8 and an increase of LXA4
concentrations. An inverted correlation was found between the
IL-8 and LXA4 levels.
The real efficiency of antipseudomonal antibiotic in acute
respiratory exacerbations of CF patients has been asked [11].
However, most of the reports are indicating decreased bacterial
density in sputum and improved pulmonary function after
antibiotic treatment of pulmonary exacerbation in CF [12].
Redding and co-workers first showed that FVC and FEV1
improved significantly after 2 weeks of IV antibiotics [13].
Since then, numerous studies have shown that 2 weeks of IV
antibiotic therapy, improved the FEV1 while density of P.
aeruginosa decreased significantly [9,14]. More recently it was
shown that the combination of IV beta-lactam and an amino-
glycoside produced a longer and better improvement of the
respiratory function and bacterial infection remission than beta-
lactam alone [15]. The 6% increase of FEV1 and 4.3 log10 CFU/
glog10CFU/g decrease in bacterial density obtained in our study
are consistent with these previous data.Our study provided additional data on the effect of IV anti-
biotic on inflammatory markers. The neutrophilic inflammation
and increased production of pro-inflammatory mediators in CF
have been largely reported [7,16]. However, contradicting re-
sults exist over the respective roles of infection and inflamma-
tion in the CF airways. No significant change in sputum IL-8
levels of CF patients between respiratory exacerbations and
periods of well-being have been reported [17]. Some investi-
gators have shown that airway inflammation can be present
without evidence of ongoing infection [18]. However, numer-
ous studies are suggesting that bacterial infection precedes
development of airway inflammation and is correlated with the
degree of inflammation [19,20]. Regardless of whether infec-
tion or inflammation comes first, it is thought that the CF
epithelium has an exaggerated inflammatory response to infec-
tion which persists long after the stimulus is withdrawn [21].
Markers of airway infection and inflammation may be more
sensitive than pulmonary function to determine the efficacy of new
therapies and may help to understand the antibiotic mechanism of
action. Bacterial density and airway inflammation have been
measured from either expectorated sputum or bronchoalveolar
lavage specimens. However the bronchoscopy necessary for
bronchoalveolar lavage collection requires general anesthesia or
conscious sedation making it less acceptable for the patients.
Moreover, there is little or no data on the reproducibility of
inflammatory markers in bronchoalveolar lavage fluid. Although
easier to obtain and generally more acceptable to subjects, ex-
pectorated sputum samples are useful in the majority of situations.
Several studies have shown that the sputum collection procedures
and the assay methods are highly reproducible [22–24].
Our study indicated that IV antibiotics treatment for pulmo-
nary exacerbation in CF patients resulted in a significant de-
creased in neutrophil counts and IL-8 levels as it has been
demonstrated by others [25,26]. In our study, the median IL-8
decreased significantly after antibiotics but the decrease was not
observed for all patients. Despite the precaution taken to use a
reproducible method in sample collection, it cannot be excluded
that individual differences were due to variability in the lung
area where the sputum arise. These differences could also be
attributed to a true heterogeneity of individual responses and
might explain the controversial results previously reported. No
modulation of bronchoalveolar lavage markers of inflammation
(IL-6 and IL-8) could be demonstrated in young children with
CF who had been treated by 1 month inhaled tobramycin [27].
Beside IL-8 production in the airway, we investigated the
possible effect of antibiotics on LXA4 level in the sputum. We
have shown for the first time that antibiotics treatment is
significantly associated with a significant increase of the anti-
inflammatory mediator, LXA4 in the spontaneous sputum of CF
patients. Furthermore, we found an inverted correlation between
the IL-8 and LXA4 levels. In the cases where antibiotics did not
significantly affect the IL-8 level, the LXA4 was not affected
either. The correlation between the concentrations of these 2
mediators might be explained by an inhibitory effect of LXA4
on IL-8 production as reported by others [3].
Lower LXA4 levels have been measured in the bronchoal-
veolar lavages of CF patients compared to patients with other
467R. Chiron et al. / Journal of Cystic Fibrosis 7 (2008) 463–468inflammatory lung diseases and same pro-inflammatory (IL-8
level) profile [5]. In another report, no difference in LXA4 levels
were found between CF and healthy subjects, however lower
LXA4 level in CF patients with a high neutrophil count
compared to CF patients with a low neutrophil count were
reported [6]. LXA4 inhibits neutophils accumulation and the P.
aeruginosa stimulated IL-8 release by airway epithelial cells
[5]. LXA4 also inhibits the TNF-α induced IL-8 release by
PBMC [3]. LXA4 is produced by lipoxygenases interaction
from different cell types including neutrophils and epithelial
cells. Since the neutrophil count (and total cell count) was
significantly decreased after antibiotics treatment, the stimula-
tory effect of antibiotics was even more pronounced when the
LXA4 concentration was expressed as the LXA4/neutrophil
ratio, as used by others [5,6]. The cellular mechanisms involved
in the LXA4 fluctuations in CF are not understood and the
concept of a defective LXA4 as a primary defect in CF lung
disease need further studies before to be asses. However, we
have shown that LXA4 levels were inversely related to the
sputum inflammatory markers of CF patients.
In a previous study, we reported that LXA4 stimulated an
intracellular Ca2+ signal and a subsequent Ca2+-activated Cl−
secretion in human airway epithelial cells suggesting that LXA4
could also stimulate the airway mucociliary clearance [28].
Therefore, in addition to its anti-inflammatory effects, the in-
crease LXA4 levels measured after antibiotics treatment might
also enhanced the airway lumen hydration which is altered in
CF due to CFTR gene mutation. The possible effect of anti-
biotics on mucus clearance is then questioned and has been
poorly investigated so far [29,30]. Although, the duration of the
change in LXA4 in the sputum after antibiotics need further
investigations. Our results might initiate a new understanding of
the pathophysiology of CF and the role of antibiotics in the
treatment of this disease.
In conclusion, our study provides evidence of a correlation
between antibiotics treatment, lung function and inflammatory
markers. These results indicate that inflammatory mediators
measurement in sputum may be use as non-invasive out come to
asses a response to antibiotics therapy of a pulmonary exacer-
bation in CF. These data also provided evidence for a novel effect
of antibiotic in regulating LXA4 concentration in the airway.
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